Elevated serum concentrations of CA-125 in patients with advanced endometriosis

Barbieri, Robert L.; Niloff, Jonathan M.; Bast, Robert C.; Scaetzl, E.; Kistner, Robert W.; Knapp, Robert C.

doi:10.1016/s0015-0282(16)49333-7

Cited by 309 publications

(141 citation statements)

References 7 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…Increased serum levels of CA 125 were first detected in patients with invasive epithelial ovarian cancer. Successively, elevated CA 125 levels were also observed in the serum, menstrual effluent, and peritoneal fluid of women with endometriosis (1,2). However, the sensitivity of serum CA 125 assessment is too low for it to be used as a screening or diagnostic test for endometriosis (3).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Serum CA 125 Levels in Patients with Pelvic Pain Related to Endometriosis

et al. 2007

View full text Add to dashboard Cite

The aim of the study was to investigate the clinical value of the serum CA 125 level for diagnosing and determining the severity of endometriosis and pelvic pain associated with endometriosis. Eighty-six women who underwent operative laparoscopy were enrolled. Sixty-nine women with endometriosis and 17 without endometriosis participated in this study. In all of the patients, endometriosis was diagnosed and classified into stages according to the Revised American Fertility Society (R-AFS) classification. The mean serum CA 125 levels were determined in each patient. We also investigated the relationship between serum CA 125 concentration and the intensity of dysmenorrhea and dyspareunia in the study group. The mean serum CA 125 levels of women with endometriosis were higher than those of the control group (p<0.050). However, the mean serum CA 125 levels were higher in stage IV than in other stages of endometriosis according to the R-AFS classification. On the other hand, the percentage of patients with serum CA 125 levels >35 U/mL was elevated in the subgroups with severe dyspareunia and severe dysmenorrhea versus the asymptomatic subgroup but the differences had no statistical significance. In conclusion, CA 125 serum levels were related to endometriosis and R-AFS score in the evaluated patient series. No correlation was found between serum levels of CA 125 and pelvic pain in patients with endometriosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of Serum CA 125 Levels in Patients with Pelvic Pain Related to Endometriosis

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Cytologic evaluation of cervical, vaginal, or peritoneal fluids (15)(16)(17)(18), pelvic examination (19)(20)(21), transabdominal, transvaginal, and color Doppler sonography (22,23), and numerous biomarkers (24,25) have been studied as potential screening and diagnostic tests for EOC. However, these modalities are not endowed individually with sufficient test sensitivity and specificity (accuracy) to be recommended for population-based screening of ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

“…However, elevated serum CA125 levels are not restricted to EOC. Notably, serum CA125 levels are elevated in various normal and pathologic conditions that affect the endometrium, including menstruation (46)(47)(48)(49)(50), pregnancy (51)(52)(53)(54)(55)(56), endometriosis (20,42,(57)(58)(59)(60)(61), and endometrial cancer (58,62,63). Serum CA125 levels also are elevated in patients with benign and inflammatory diseases of the liver (64,65), pelvis (66), uterus (58), and ovary (42,53,58,67), and in patients with hematologic, bladder, breast, fallopian, gastrointestinal, liver, lung, and pancreatic cancers (68)(69)(70).…”

Section: Introductionmentioning

confidence: 99%

Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer

Baron

Boardman

Lafky³

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is the leading cause of death among all gynecologic cancers in the United States. Because women who are diagnosed with early stage disease have a better prognosis than women diagnosed with late stage disease, early detection represents a potentially practical approach to reduce the mortality associated with EOC. Unfortunately, no single screening test has proven to be effective for this purpose, and a valid and feasible screening program to detect early stage EOC in the general population has not yet been devised. Consequently, research has focused on coupling two or more screening modalities to improve program validity and feasibility. Serum cancer antigen 125 (CA125) and a soluble isoform of the epidermal growth factor receptor (p110 sEGFR) have been studied individually as biomarkers of ovarian cancer. In this study, we compare serum CA125 levels and sEGFR concentrations in women with EOC to women with benign gynecologic conditions of ovarian and non-ovarian origin. We show that serum sEGFR concentrations are lower in patients with EOC than in women with benign gynecologic conditions, whereas serum CA125 levels are higher in patients to EOC compared with women with benign gynecologic conditions. These data also reveal that age and serum sEGFR concentrations modify the association between CA125 levels and EOC versus benign gynecologic disease. Hence, age-and sEGFR-dependent CA125 cutoff thresholds improve the ability of CA125 to discern EOC patients from women with benign ovarian tumors and non-ovarian gynecologic conditions. Our analyses show that parallel testing with fixed sEGFR and CA125 cutoff thresholds optimizes sensitivity to detect EOC, whereas serial testing with age-and sEGFR-dependent CA125 cutoff thresholds optimizes test specificity, and overall accuracy to discern patients with EOC from women with benign ovarian and non-ovarian gynecologic conditions. The combined use of serologic sEGFR and CA125, thus, has improved utility for screening and diagnosing EOC, which may increase the positive predictive value of a multimodal screening program that incorporates these biomarkers to detect and subsequently differentiate benign from malignant ovarian tumors. (Cancer Epidemiol Biomarkers Prev 2005;14(2):306 -18)

show abstract

“…Twenty-eight additional consecutive pregnant patients without matched pairs were included to compare different pregnancy outcomes. Since CA-125 concentrations are known to be elevated in endometriosis (10), no endometriosis patients were included.…”

Section: Methodsmentioning

confidence: 99%

Prognostic value of serum CA-125 measurements on stimulation day 1 and on the day of oocyte pickup in the prediction of IVF treatment outcome

Hauzman

Lagarde

Nagy

et al. 2005

J Assist Reprod Genet

View full text Add to dashboard Cite

Elevated serum concentrations of CA-125 in patients with advanced endometriosis

Cited by 309 publications

References 7 publications

Evaluation of Serum CA 125 Levels in Patients with Pelvic Pain Related to Endometriosis

Evaluation of Serum CA 125 Levels in Patients with Pelvic Pain Related to Endometriosis

Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer

Prognostic value of serum CA-125 measurements on stimulation day 1 and on the day of oocyte pickup in the prediction of IVF treatment outcome

Contact Info

Product

Resources

About